Literature DB >> 17653720

The classification of fibromyalgia syndrome.

W Müller1, E M Schneider, T Stratz.   

Abstract

As has been shown by a number of working groups, primary fibromyalgia syndrome does not represent a single clinical entity. It is possible to distinguish between a subgroup with high pain sensitivity and no associated psychiatric condition, a second and a third subgroup characterized by depression associated with fibromyalgia syndrome, and a fourth group with somatoform pain disorder of the fibromyalgia type. Mild inflammatory processes must be considered as the cause in the first group, while depression is combined with fibromyalgia in the second and the third group. In the fourth group, serious previous or still existing psychological problems or also insufficient coping with illness symptoms must be regarded as the reason for pain chronification. Group 1 benefits from a blocking of the 5-HT3 receptors by means of tropisetron, for example. This does not only affect pain chronification but also the inflammatory process itself. Group 2 and 3 needs antidepressant treatment, whereas the focus should be on psychotherapy in group 4. Groups 1, 2 and 3 will also profit from multimodal physical treatment programs, to a certain extent this applies to group 4 as well. So-called mixed types require a combination of therapeutic measures.

Entities:  

Mesh:

Year:  2007        PMID: 17653720     DOI: 10.1007/s00296-007-0403-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  30 in total

1.  The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.

Authors:  Karla P Zeitz; Nicolas Guy; Annika B Malmberg; Sahera Dirajlal; William J Martin; Linda Sun; Douglas W Bonhaus; Cheryl L Stucky; David Julius; Allan I Basbaum
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 2.  Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions.

Authors:  J M Mullington; D Hinze-Selch; T Pollmächer
Journal:  Ann N Y Acad Sci       Date:  2001-03       Impact factor: 5.691

3.  A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Authors:  Lesley M Arnold; Amy Rosen; Yili Lu Pritchett; Deborah N D'Souza; David J Goldstein; Smriti Iyengar; Joachim F Wernicke
Journal:  Pain       Date:  2005-11-17       Impact factor: 6.961

Review 4.  The relationship between fibromyalgia and major depressive disorder.

Authors:  J I Hudson; H G Pope
Journal:  Rheum Dis Clin North Am       Date:  1996-05       Impact factor: 2.670

5.  Operant behavioral treatment of fibromyalgia: a controlled study.

Authors:  Kati Thieme; Erika Gromnica-Ihle; Herta Flor
Journal:  Arthritis Rheum       Date:  2003-06-15

6.  Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes.

Authors:  B L Fiebich; R S Akundi; K Lieb; E Candelario-Jalil; D Gmeiner; U Haus; W Müller; T Stratz; E Muñoz
Journal:  Scand J Rheumatol Suppl       Date:  2004

7.  [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].

Authors:  Th Stratz; W Müller
Journal:  Fortschr Med Orig       Date:  2002

Review 8.  Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.

Authors:  Philip Mease
Journal:  J Rheumatol Suppl       Date:  2005-08

9.  Assessing depression in fibromyalgia patients.

Authors:  C S Burckhardt; C A O'Reilly; A N Wiens; S R Clark; S M Campbell; R M Bennett
Journal:  Arthritis Care Res       Date:  1994-03

Review 10.  Fibromyalgia: present to future.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2004-10
View more
  9 in total

Review 1.  [Pain and anesthesiology : aspects of the development of modern pain therapy in the twentieth century].

Authors:  W Witte
Journal:  Anaesthesist       Date:  2011-06       Impact factor: 1.041

2.  Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study.

Authors:  Juliana Barcellos de Souza; Philippe Goffaux; Nancy Julien; Stephane Potvin; Jacques Charest; Serge Marchand
Journal:  Rheumatol Int       Date:  2008-09-27       Impact factor: 2.631

3.  Profiles in fibromyalgia: algometry, auditory evoked potentials and clinical characterization of different subtypes.

Authors:  Yolanda Triñanes; Alberto González-Villar; Claudio Gómez-Perretta; María T Carrillo-de-la-Peña
Journal:  Rheumatol Int       Date:  2014-04-11       Impact factor: 2.631

4.  Use of the Short-Form-36 Health Survey to detect a subgroup of fibromyalgia patients with psychological dysfunction.

Authors:  Jürg Oswald; Souzan Salemi; Beat A Michel; Haiko Sprott
Journal:  Clin Rheumatol       Date:  2008-04-01       Impact factor: 2.980

Review 5.  Acupuncture for treating fibromyalgia.

Authors:  John C Deare; Zhen Zheng; Charlie C L Xue; Jian Ping Liu; Jingsheng Shang; Sean W Scott; Geoff Littlejohn
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

6.  The interest of gait markers in the identification of subgroups among fibromyalgia patients.

Authors:  Bernard Auvinet; Denis Chaleil; Jean Cabane; Anne Dumolard; Pierre Hatron; Robert Juvin; Michel Lanteri-Minet; Yves Mainguy; Laurence Negre-Pages; Fabien Pillard; Daniel Riviere; Yves-Michel Maugars
Journal:  BMC Musculoskelet Disord       Date:  2011-11-11       Impact factor: 2.362

7.  Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise.

Authors:  Maria Elena Bote; Juan Jose Garcia; Maria Dolores Hinchado; Eduardo Ortega
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

8.  Trapezius activity of fibromyalgia patients is enhanced in stressful situations, but is similar to healthy controls in a quiet naturalistic setting: a case-control study.

Authors:  Rolf Harald Westgaard; Paul Jarle Mork; Håvard Wuttudal Lorås; Roberto Riva; Ulf Lundberg
Journal:  BMC Musculoskelet Disord       Date:  2013-03-18       Impact factor: 2.362

9.  Audiovestibular Dysfunction in Patients with Fibromyalgia Syndrome.

Authors:  Mehbube Tuncer; Kübra Çoban; Selim S Erbek; H Seyra Erbek
Journal:  J Int Adv Otol       Date:  2021-07       Impact factor: 1.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.